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Abstract
Objectives
To identify non-invasive predictors of response to tamsulosin 0.4 mg in patients with benign prostatic
obstruction (BPO).
Methods
Males ≥ 50 years of age with lower urinary tract symptoms (LUTS) suggestive of BPO for over three months
were included in the study. We assessed change in the mean International Prostate Symptom Score (IPSS)
and maximum flow rate (Qmax) after six weeks of medical therapy. Clinical and uroflowmetry parameters
were compared between two groups of patients with >25% vs. <25% change in the IPSS after treatment. Pre-
and post-treatment post-void residue (PVR), Qmax, and IPSS were compared by independent t-test,
univariate/multivariate regression analysis.
Results
A total of 121 patients were included. At presentation, the mean prostate size was 35.7±12.2 grams and the
mean IPSS was 16.3 ± 4.8. Improvement in the mean IPSS was 7.83, with more marked improvement in
storage compared to voiding LUTS (5.26 vs. 2.57). Majority (58%) had a quality of life (QoL) score of 4-5 at
presentation whereas after 6-weeks of medication (83.5%) had a QoL score of 0-2. Treatment failure was
noted in 11 (9.1%) patients. IPSS was higher and Qmax was lower at the time of presentation in patients who
had <25% improvement. However, the two groups were identical on the basis of demographic and other
factors (BMI, age, prostate size, PVR).
Conclusion
Moderate LUTS secondary to BPO responds favourably to alpha-blocker (tamsulosin 0.4 mg) treatment.
Uroflowmetry (UFM) parameters, that is, Qmax and IPSS are important factors in predicting short-term
response to medical therapy.
Categories: Urology
Keywords: benign prostatic obstruction, alpha-blockers, predictors
Introduction
Benign prostatic obstruction (BPO) is a progressive disease often observed in men over 50 years of age.
Enlargement of the prostate does not affect all men in a similar fashion [1]. BPO leads to a deterioration in
the quality of life by disturbing normal activities such as sleep, and may cause complications such as
recurrent UTIs, bladder stones or acute urinary retention. The most commonly performed surgical
intervention for BPO is transurethral resection of the prostate. However, it is associated with short and long
term morbidity [2]. Currently, medical treatment with alpha-blockers, 5-alpha-reductase inhibitors (5-ARIs)
either alone or in combination has become the first line of therapy. Alpha-blockers, act by relaxing the
prostatic smooth muscle and improve urination, are most commonly used for BPO patients.
Clinical and investigational workup in the evaluation of benign prostatic enlargement, besides baseline
workup, include the International Prostate Symptoms Score (IPSS), uroflowmetry and post-void residual
(PVR) urine or urodynamic studies [3].
An interventional urodynamic study, in particular pressure flow study, is the gold standard in the diagnosis
of BPO secondary to BPH. Predictors of response to therapy are useful in stratifying patients for first-line
medical versus surgical treatment [4]. These predictors can be classified as invasive and non-invasive. In
some men, the symptoms are difficult to manage with medical therapy while others respond remarkably well
to alpha-blockers + 5ARIs. This may be the result of different morphological characteristics of prostatic
enlargement. Morphologically four types of prostatic enlargement are described such as isolated lateral or
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median lobe enlargement, lateral and middle lobe enlargement or posterior commissural hyperplasia [5].
There are several non-invasive tests available for the diagnosis of BPO in order to avoid the morbidity
associated with invasive urodynamics. However, there is uncertainty concerning the diagnostic accuracy of
these tests. Most of the guidelines endorse these tests as “mandatory” or “recommended” in the clinical
evaluation of men with BPO. In a systematic review by Malde et al [6], authors noted high sensitivity and
specificity of evaluation of detrusor wall thickness, near-infrared spectroscopy and the penile cuff test in
diagnosing BPO.
We conducted this study to assess improvement in IPSS and determine predictors of urinary retention and
the need for intervention in patients on medical treatment with alpha-blocker tamsulosin hydrochloride.
Results of this study will help in counselling of management and the need for intervention.
Materials And Methods
We performed a cross-sectional study at the Department of Urology in a University Hospital. After ethical
review committee approval, patients above 50 years of age presenting with lower urinary tract symptoms
(LUTS) suggestive of BPO for more than three months were included. We excluded patients already on any
medical therapy, patients with bladder stone, urinary tract infection, neurogenic bladder or urethral
stricture. Patients who had an intervention for prostatic obstruction previously or who were unable to
perform uroflowmetry (UFM) were also excluded. Data were collected over a period of nine months. Non-
probability consecutive sampling technique was employed. The primary outcomes were improvement in
mean IPSS and Qmax after six weeks. Secondary outcomes were urinary retention or need for surgery. The
IPSS consists of seven questions that deal with voiding symptoms (incomplete emptying, intermittency,
weak stream and straining to void) and storage symptoms (frequency, urgency and nocturia) in addition to
another question, looking at the effect on the quality of life (QoL).
Data were analysed using SPSS version 25 (IBM Corp., Armonk, NY). Descriptive analyses for quantitative
variables were reported as mean and SD, categorical variables such as basic demographic, clinical and other
desired characteristics were reported as frequency and percentages. The pre- and post-treatment PVR,
Qmax, and IPSS were reported as mean ± SD and were assessed by the independent t-test. P-value of less
than 0.05 was considered statistically significant.
Response to medical therapy was seen in terms of improvement in IPSS at six weeks. Responders were
defined as an overall improvement of ≥25% in IPSS score after six weeks. Predictors of response were
identified with logistic regression analysis.
Results
A total of 121 patients were included in our study. Mean age was 62.87 ± 8.78 and mean BMI was 26.05 ±
3.78. Thirty-five (29%) men were diabetic. The mean prostate size was 35.7g ± 12.2. Most patients (80%) had
an IPSS of 8-18 (moderate score) on presentation.
In Table 1, the pre- and post-treatment parameters are described. Mean improvement in IPSS of 7.83 was
noted after six weeks of tamsulosin, with more marked improvement in storage symptoms as compared to
voiding symptoms (5.26 vs. 2.57). More than half of the patients (58%) had a QoL score of 4-5 (mostly
unsatisfied/unhappy) at presentation whereas after six weeks of medication 83.5% had a QoL score of 0-2
(delighted/pleased/mostly satisfied). Treatment failure was noted in 11 (9.10%) patients. One patient
developed urinary retention and the remaining 10 patients did not have any improvement in symptoms and
were advised interventional treatment.
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Variable Pre-treatment Post-treatment P-value
IPSS 16.27 ± 4.78 8.45 ± 5.37 0.001
IPSS storage 9.28 ± 2.20 4.02 ± 2.48 0.001
IPSS voiding 7.0 ± 3.10 4.42 ± 3.11 0.001
QoL 4.14 ± 1.11 1.81 ± 1.16 0.001
PVR 77.09 ± 57.24 33.74 ±34.24 0.001
Qmax 10.41 ± 3.45 14.69 ± 5.53 0.001
Qavg 5.01 ± 3.45 8.02 ± 3.52 0.001
TABLE 1: Pre-treatment and post-treatment parameters.
IPSS: International Prostate Symptoms Score; QoL: quality of life; PVR: post-void residue.
The group with >25% improvement in IPSS score was compared with those who had <25% improvement, no
significant difference was found with regards to age, BMI and prostate size. However, a higher IPSS and PVR
and lower Qmax and Qavg at the time of presentation were significant predictors of poorer response (<25%
improvement in IPSS) (Table 2). On multivariate regression analysis, Qmax and IPSS at the time of




N = 18 (15%) N = 103(85%)
Age 63.50 ± 9.87 62.77 ± 8.52 0.67
BMI 25.81 ± 4.02 24.91 ± 3.74 0.84
Prostate size at presentation 35.36 ± 9.42 35.71 ± 12.68 0.55
PVR at presentation 106.71 ± 57.72 71.91 ± 55.83 0.27
IPSS storage 11.12 ± 2.09 8.97± 1.97 0.01
IPSS voiding 9.77 ± 4.14 6.50 ± 2.70 0.04
IPSS pre treatment 20.89 ± 5.93 15.47 ± 4.08 0.01
Quality of life 4.61 ± 1.20 3.70 ± 0.80 0.05
Qmax. at presentation 7.99 ± 3.29 10.82 ± 5.31 0.03
Avg. flow at presentation 3.48 ± 1.66 5.29 ± 1.72 0.04
TABLE 2: Comparison of the non-invasive parameters in the groups.
IPSS: International Prostate Symptoms Score; PVR: post-void residue.
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Variable Univariate analysis Multivariate analysis
 OR 95% CI P-value OR 95% CI P-value
Post-void residue 0.96 0.96 0.99 0.02 0.99 0.98 1.00 0.66
Prostate volume 1.00 0.96 1.04 0.91  
Qmax. 1.51 1.84 1.94 0.01 1.28 1.01 1.62 0.03
QoL 0.34 0.19 0.62 0.01 0.98 0.41 2.33 0.96
IPSS 0.81 0.72 0.90 0.01 0.83 0.71 0.97 0.02
TABLE 3: Univariate and multivariate regression analysis.
IPSS: International Prostate Symptoms Score; QoL: quality of life.
Discussion
Lower urinary tract symptoms are a common presentation in a urological clinic. Significant proportion of
these patients have BPO. Alpha-blockers are the mainstay of medical treatment along with lifestyle
modifications. Men with detrusor hyperactivity respond better to combination treatment with α-blocker
with an anticholinergic rather than monotherapy [7]. Combination treatment also makes use of PDE5
inhibitors (even in the absence of erectile dysfunction)[8] and 5 ARIs for larger gland sizes. Nevertheless, a
significant proportion of these patients do not respond to the first-line medical treatment. There are
multiple reasons for medical treatment failure and prediction of success is helpful in instituting the
appropriate treatment on time.
In order to improve the efficacy of medical management, it is important to first and foremost determine
whether these symptoms are due to BPO. The gold standard in the diagnosis of BPO is pressure-flow study
[9]. However, it is invasive, cumbersome and expensive. Most current guidelines recommend the use of
invasive urodynamic only in the select group of patients with equivocal outcome from non-invasive tests or
in patients with associated medical conditions that could be the cause of underlying neurogenic bladder
dysfunction [10]. Multiple studies have considered predictors of failure of medical therapy using non-
invasive tests. These include intra-vesical prostatic protrusion, prostatic urethral angle (PUA), non-invasive
urodynamic parameters, PVR, IPSS bladder wall thickness, etc [1,2,11,12,13].
However, in a clinical setting, only limited workup is available at initial presentation as recommended by
most urological guidelines, for example, symptom score questionnaires, frequency volume chart
(FVC), digital rectal examination(DRE) [14]. In the current study, we attempted to identify factors, which
have the potential to predict response to medical therapy.
We found that IPSS at the time of presentation is significant when differentiating potential responders and
non-responders to Tamsulosin treatment. However other studies showed that there is a poor correlation of
IPSS to bladder outlet obstruction but patient reported symptoms in terms of IPSS do help in deciding
appropriate management to some extent [15]. It was interesting to note that improvement in IPSS was less
significant in voiding symptoms, which is similar to studies reporting a poor correlation of IPSS with
voiding symptoms in patients with BPO [16,17]. We also found that Qmax at the time of presentation is also
a significant predictor of response to tamsulosin treatment. In our study, Qmax less than 8 did not
show improvement in IPSS and can be correlated with BPO. However, one study reported a Qmax < 4.5
mL/sec that was considered obstructed. Similarly, patients with Qmax of more than 11 ml/sec showed
significant improvement in IPSS in our study in comparison to Qmax of 13.8 ml/sec reported in the
literature [18]. In our study, prostate size and PVR are not significant predictors of poor response which is
contrary to other studies reporting the prostate size and PVR [1,19] are significant predictors of failure of
medical therapy. Although PVR alone cannot predict BPO as these patients do often have detrusor under-
contractility [20,21] and the sensitivity and specificity of prostate volume as a predictor of BPO is very
low [22].
In our study, only short-term response to medical therapy was assessed and in long-term factors found
insignificant, may still be important. We only considered the clinically available workup for stratifying
responders and did not include any interventional/investigational factors like urodynamics, which although
ideal but usually not required in most patients presenting to a urology clinic. Results of this study will help
patients in further deciding their treatment options at least in short term with the help of easily available,
safe and quick non-invasive tools. It is a single-center study, so our results may not be applicable to patients
who require more extensive workup, for example, those with the underlying neurological condition. 
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Conclusions
In the literature, extensive work has been done and most patients presenting with moderate LUTS secondary
to benign prostatic obstruction respond favourably to alpha-blocker treatment. In our study, we also
determined that UFM parameters specially Qmax and IPSS are important factors in predicting short-term
response to medical therapy.
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